文献速递痛风与晶体性关节病

选择性URAT1抑制剂SHR4640治疗中国高尿酸血症的随机对照II期研究

Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该随机双盲剂量探索II期研究纳入高尿酸血症中国受试者,比较SHR4640 2.5/5/10 mg、苯溴马隆50 mg与安慰剂的疗效安全性;第5周5 mg和10 mg SHR4640组达标sUA≤360 µmol/l比例显著高于安慰剂,降sUA幅度更大,耐受性良好。

要点

  • 5 mg和10 mg SHR4640第5周sUA≤360 µmol/l达标率分别为32.5%和72.5%,均显著高于安慰剂0%。
  • 5 mg、10 mg SHR4640及苯溴马隆组sUA分别降低32.7%、46.8%、41.8%,均显著优于安慰剂5.9%。
  • 各组需干预的痛风发作发生率相似,TEAE发生率相当,未报告严重TEAE。

核心结论

  • 每日一次5 mg或10 mg SHR4640治疗5周较安慰剂显著降低中国高尿酸血症受试者sUA并提高达标率,且耐受性良好。

研究设计与样本

  • 随机双盲剂量探索II期研究,受试者为sUA≥480 µmol/l伴痛风、≥480 µmol/l不伴痛风但有合并症或≥540 µmol/l的中国高尿酸血症者。
  • 受试者按1:1:1:1:1随机接受每日一次SHR4640 2.5 mg、5 mg、10 mg、苯溴马隆50 mg或安慰剂。
  • 主要终点为第5周达到目标sUA≤360 µmol/l的受试者比例。

主要发现

  • 共197例受试者,99.5%为男性,95.9%有痛风史。
  • 第5周达标sUA≤360 µmol/l比例:SHR4640 5 mg组32.5%、10 mg组72.5%、苯溴马隆组61.5%,安慰剂组0%;5 mg和10 mg SHR4640组与安慰剂比较P<0.05。
  • 第5周sUA降低幅度:SHR4640 5 mg组32.7%、10 mg组46.8%、苯溴马隆组41.8%,安慰剂组5.9%;各比较P<0.001。
  • 各组需干预的痛风发作发生率相似,TEAE发生率相当,未报告严重TEAE。

关键数值与推荐

  • 主要终点为第5周sUA≤360 µmol/l的受试者比例。
  • 入组sUA阈值:伴痛风≥480 µmol/l,不伴痛风但有合并症≥480 µmol/l,或≥540 µmol/l。

临床怎么用

  • 在中国高尿酸血症(尤其男性、有痛风史)人群中,SHR4640 5 mg或10 mg每日一次治疗5周可显著降sUA并提高达标率。
  • SHR4640 5 mg和10 mg的降sUA效果与苯溴马隆50 mg可比,耐受性良好。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of SHR4640, a highly selective urate transporter 1 inhibitor, in Chinese subjects with hyperuricaemia. METHODS: This was a randomized double-blind dose-ranging phase II study. Subjects whose serum uric acid (sUA) levels were ≥480 µmol/l with gout, ≥480 µmol/l without gout but with comorbidities, or ≥540 µmol/l were enrolled. Subjects were randomly assigned (1:1:1:1:1) to receive once daily 2.5 mg, 5 mg, 10 mg of SHR4640, 50 mg of benzbromarone or placebo, respectively. The primary end point was the proportion of subjects who achieved target sUA level of ≤360 µmol/l at week 5. RESULTS: 99.5% of subjects (n = 197) were male and 95.9% of subjects had gout history. The proportions of subjects who achieved target sUA at week 5 were 32.5%, 72.5% and 61.5% in the 5 mg, 10 mg SHR4640 and benzbromarone groups, respectively, significantly higher than the placebo group (0%; P < 0.05 for 5 mg and 10 mg SHR4640 group). The sUA was reduced by 32.7%, 46.8% and 41.8% at week 5 with 5 mg, 10 mg SHR4640 and benzbromarone, respectively, vs placebo (5.9%; P < 0.001 for each comparison). The incidences of gout flares requiring intervention were similar among all groups. Occurrences of treatment-emergent adverse events (TEAEs) were comparable across all groups, and serious TEAEs were not reported. CONCLUSIONS: The present study indicated a superior sUA-lowering effect and well tolerated safety profile after 5-week treatment with once-daily 5 mg/10 mg of SHR4640 as compared with placebo in Chinese subjects with hyperuricaemia. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT03185793.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lin Y, Chen X, Ding H, et al. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. Rheumatology (Oxford). 2021. PMID: 33693494. doi:10.1093/rheumatology/keab198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。